Literature DB >> 11821474

Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.

Pia Raanani1, John M Goldman, Isaac Ben-Bassat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11821474     DOI： 10.1200/JCO.2002.20.3.869

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Selective effect of imatinib on serum IgM in a patient with CML.

Authors:  Masayuki Nagasawa; Shuki Mizutani
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 2.  Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Authors:  Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2017-09-14       Impact factor: 11.527

3.  Hypopigmentation in an African patient treated with imatinib mesylate: a case report.

Authors:  Syed Hasan; Kimberly Dinh; Fred Lombardo; Fitzroy Dawkins; John Kark
Journal:  J Natl Med Assoc       Date:  2003-08       Impact factor: 1.798

4.  Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.

Authors:  Hawk Kim; Heung-Moon Chang; Min-Hee Ryu; Tae-Won Kim; Hee-Jung Sohn; So-Eun Kim; Hye-Jin Kang; Sarah Park; Jung-Shin Lee; Yoon-Koo Kang
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

5.  Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.

Authors:  Tariq I Mughal; Andrew Schrieber
Journal:  Biologics       Date:  2010-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.